NOXAFIL
Total Payments
$3.9M
Transactions
4,479
Doctors
1,411
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $476,782 | 8 | 1 |
| 2023 | $394,071 | 45 | 1 |
| 2022 | $217,475 | 33 | 0 |
| 2021 | $226,624 | 26 | 1 |
| 2020 | $249,431 | 174 | 8 |
| 2019 | $482,924 | 526 | 291 |
| 2018 | $743,694 | 1,587 | 767 |
| 2017 | $1.1M | 2,080 | 895 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 876 | 80.5% |
| Consulting Fee | $524,793 | 89 | 13.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $82,015 | 26 | 2.1% |
| Food and Beverage | $52,938 | 3,373 | 1.4% |
| Travel and Lodging | $51,578 | 81 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $50,675 | 34 | 1.3% |
Payments by Type
Research
$3.1M
876 transactions
General
$761,998
3,603 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous IV and Powder for Oral Suspension Formulations of Posaconazole POS in Immunocompromised Pediatric Subjects with Neutropenia | Merck Sharp & Dohme Corporation | $743,364 | 0 |
| A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Phase 3 Protocol No. MK-5592-069 | Merck Sharp & Dohme Corporation | $488,053 | 0 |
| STUDY NAME#A MULTICENTER RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF POSACONAZOLE IN GENETICALLY-DEFINED PATIENTS WITH ACTIVE CROHN'S DISEASE | Merck Sharp & Dohme LLC | $411,180 | 0 |
| A SINGLE-CENTER OPEN-LABEL PROSPECTIVE PILOT STUDY OF POSACONAZOLE IN GENETICALLY-DEFINED PATIENTS WITH ACTIVE CROHN'S DISEASE | Merck Sharp & Dohme LLC | $349,503 | 0 |
| A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents Phase 3 Protocol No. MK-5592-069 | Merck Sharp & Dohme Corporation | $256,158 | 0 |
| A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole POS, MK-5592 Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection | Merck Sharp & Dohme LLC | $180,931 | 0 |
| A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in Pediatric Participants Aged 2 to less than 18 Years With Invasive Aspergillosis | Merck Sharp & Dohme Corporation | $143,749 | 0 |
| A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole POS, MK-5592 Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection | Merck Sharp & Dohme Corporation | $139,322 | 0 |
| A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in Pediatric Participants Aged 2 to less than 18 Years With Invasive Aspergillosis | Merck Sharp & Dohme LLC | $137,068 | 0 |
| Retrospective Observational Study to Evaluate Real World Effectiveness of Posaconazole Prophylaxis in patients with hematological Malignancies at Duke University Hospital | Merck Sharp & Dohme Corporation | $105,990 | 0 |
| Posaconazole Alone and in Combination with Caspofungin for Treatment of Experimental Exserohilum rostratum Meningitis | Merck Sharp & Dohme Corporation | $48,474 | 0 |
| Real World Evidence of Posaconazole in the US | Merck Sharp & Dohme Corporation | $47,500 | 0 |
| Defining the clinical, diagnostic, treatment, and outcomes among patients with epidemic mold infections in the US following contaminated methylprednisolone injections MSG-08 | Merck Sharp & Dohme Corporation | $25,000 | 0 |
| A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole POS, MK-5592 Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection | Merck Sharp & Dohme Corporation | $19,092 | 0 |
| A Retrospective Observational Study to Evaluate Real World Effectiveness of Posaconazole Prophylaxis in patients with hematological Malignancies at Duke University Hospital | Merck Sharp & Dohme Corporation | $18,500 | 0 |
| A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in Pediatric Participants Aged 2 to 18 Years With Invasive Aspergillosis | Merck Sharp & Dohme Corporation | $10,000 | 0 |
| A relative bioavailability study with MK-5592 to compare the pharmacokinetics of a pediatric oral formulation in the presence and absence of food with a tablet formulation in the absence of food in healthy adults PN-0106 | Merck Sharp & Dohme Corporation | $6,480 | 0 |
| Phase IB study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia | Merck Sharp & Dohme LLC | $6,315 | 0 |
| Phase IB study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia | Merck Sharp & Dohme Corporation | $4,000 | 0 |
| A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) | Merck Sharp & Dohme Corporation | $3,088 | 0 |
Top Doctors Receiving Payments for NOXAFIL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| James Wilson | — | Akron, OH | $3.2M | 912 |
| , M.D | Diagnostic Radiology | Madison, WI | $222,400 | 21 |
| , M.D | Diagnostic Radiology | Denver, CO | $118,900 | 15 |
| , MD | Diagnostic Radiology | Denver, CO | $112,900 | 16 |
| , MD | Hematology & Oncology | New York, NY | $39,701 | 40 |
| , MD | Infectious Disease | Buffalo, NY | $33,293 | 14 |
| , M.D | Hematology & Oncology | Houston, TX | $18,012 | 20 |
| , MD | Diagnostic Radiology | Boston, MA | $10,875 | 6 |
| , M.D | Pediatrics | San Diego, CA | $10,657 | 7 |
| , M.D | Hematology & Oncology | Salt Lake City, UT | $9,480 | 12 |
| , MBBS | Diagnostic Radiology | Boston, MA | $9,200 | 5 |
| Kathleen Mullane | Infectious Disease | Burr Ridge, IL | $8,912 | 9 |
| , M.D | Medical Oncology | New York, NY | $8,844 | 9 |
| , MD, PHD | Pediatric Infectious Diseases | Chicago, IL | $8,725 | 7 |
| , M.D | Gastroenterology | Boston, MA | $7,381 | 8 |
| , MD | Internal Medicine | Durate, CA | $7,353 | 10 |
| , MD | Infectious Disease | Memphis, TN | $6,705 | 10 |
| , MD | Infectious Disease | Philadelphia, PA | $4,098 | 3 |
| , MD, MPH | Pediatric Infectious Diseases | Cincinnati, OH | $3,825 | 2 |
| , M.D | Hematology & Oncology | Columbus, OH | $3,750 | 3 |
| , MD | Hematology & Oncology | Miami, FL | $3,385 | 3 |
| , MD | Internal Medicine | New York, NY | $3,335 | 2 |
| , MD | Infectious Disease | New York, NY | $2,470 | 2 |
| , MD | Infectious Disease | San Antonio, TX | $2,210 | 2 |
| , M.D | Infectious Disease | Durham, NC | $1,300 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 1,411
- Transactions 4,479
About NOXAFIL
NOXAFIL is a drug associated with $3.9M in payments to 1,411 healthcare providers, recorded across 4,479 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $476,782 was paid across 8 transactions to 1 doctors.
The most common payment nature for NOXAFIL is "Unspecified" ($3.1M, 80.5% of total).
NOXAFIL is associated with 20 research studies, including "A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous IV and Powder for Oral Suspension Formulations of Posaconazole POS in Immunocompromised Pediatric Subjects with Neutropenia" ($743,364).